FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia
On Aug. 17, the U.S. Food and Drug Administration (FDA) approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell…